Neogenomics (NEO) director sells 5,307 shares, retains sizable stake

Rhea-AI Filing Summary

NEOGENOMICS INC director Lynn A. Tetrault sold 5,307 shares of common stock at $11.29 per share in an open-market transaction on June 9, 2026. After this sale, she directly held 91,422 common shares and indirectly held 7,000 shares through a Lynn Tetrault Rollover IRA.

She also reported equity awards that can convert into common stock, including 15,970 restricted stock units and multiple stock option grants covering tens of thousands of shares at exercise prices ranging from $8.10 to $41.76 per share with expirations between 2026 and 2036.

Insights

Equity compensation and insider-trading analyst

Director executes a modest open-market sale while retaining a sizable equity position.

Lynn A. Tetrault, a director of NEOGENOMICS INC, sold 5,307 common shares at $11.29 per share in an open-market transaction on June 9, 2026. This is the only buy/sell trade in the filing; the other entries simply restate existing holdings.

Following the sale, she directly held 91,422 common shares and 7,000 additional shares indirectly via a rollover IRA. She also retained a portfolio of equity awards, including 15,970 restricted stock units and multiple stock options with exercise prices between $8.10 and $41.76, expiring from 2026 through 2036. The filing reads as a routine disposition with substantial remaining exposure.

Insider Trade Summary 10b5-1

Net Seller: 5,307 shares ($59,916)

Net Sell 12 txns

Insider TETRAULT LYNN A.

Role null

Sold 5,307 shs ($60K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,307	$11.29	$60K
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Unit	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 91,422 shares (Direct, null); Stock Option (Right to Buy) — 2,136 shares (Direct, null); Restricted Stock Unit — 15,970 shares (Direct, null); Common Stock — 7,000 shares (Indirect, Lynn Tetrault Rollover IRA)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 5,307 shares Sale price: $11.29 per share Direct common shares after sale: 91,422 shares +5 more

8 metrics

Shares sold 5,307 shares Open-market sale of common stock on June 9, 2026 at $11.29

Sale price $11.29 per share Price for 5,307 Neogenomics common shares sold

Direct common shares after sale 91,422 shares Direct Neogenomics common stock held by Lynn A. Tetrault

Indirect common shares (IRA) 7,000 shares Common stock held via Lynn Tetrault Rollover IRA

Restricted stock units 15,970 units RSUs convertible into Neogenomics common stock, not expiring once vested

Option grant at $10.52 11,069 underlying shares Stock option with $10.52 exercise price, expiring June 1, 2036

Option grant at $7.28 16,107 underlying shares Stock option with $7.28 exercise price, expiring June 1, 2035

Highest-priced option 972 underlying shares at $41.76 Stock option expiring October 11, 2028

Key Terms

Restricted Stock Unit, Stock Option (Right to Buy), open-market sale, Rollover IRA, +1 more

5 terms

Restricted Stock Unit financial

"The filing lists a Restricted Stock Unit position with 15,970 underlying common shares."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (Right to Buy) financial

"Multiple entries show Stock Option (Right to Buy) awards over Neogenomics common stock."

open-market sale financial

"The Form 4 describes the S-code transaction as an open-market sale or private transaction."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rollover IRA financial

"7,000 common shares are held indirectly through a Lynn Tetrault Rollover IRA."

exercise price financial

"Each stock option grant discloses an exercise price, such as $10.52 or $41.76 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TETRAULT LYNN A.

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FLORIDA 33912

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		S		5,307	D	$11.29	91,422	D
Common Stock								7,000	I	Lynn Tetrault Rollover IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.52							06/06/2020	06/06/2026	Common Stock	2,136		2,136	D
Stock Option (Right to Buy)	$28.54							05/28/2021	05/28/2027	Common Stock	3,448		3,448	D
Stock Option (Right to Buy)	$40.9							06/02/2022	06/02/2028	Common Stock	3,714		3,714	D
Stock Option (Right to Buy)	$41.76							10/11/2022	10/11/2028	Common Stock	972		972	D
Stock Option (Right to Buy)	$8.1							06/10/2023	06/10/2029	Common Stock	13,882		13,882	D
Stock Option (Right to Buy)	$14.82							08/10/2024	08/10/2033	Common Stock	8,353		8,353	D
Stock Option (Right to Buy)	$13.71							06/01/2025	06/01/2034	Common Stock	8,672		8,672	D
Stock Option (Right to Buy)	$7.28							06/01/2026	06/01/2035	Common Stock	16,107		16,107	D
Stock Option (Right to Buy)	$10.52							06/01/2027	06/01/2036	Common Stock	11,069		11,069	D
Restricted Stock Unit	$0							06/01/2027	(1)	Common Stock	15,970		15,970	D

Explanation of Responses:

1. Once vested, the shares of common stock are not subject to expiration.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neogenomics (NEO) report for Lynn A. Tetrault?

Neogenomics reported that director Lynn A. Tetrault sold 5,307 shares of common stock at $11.29 per share in an open-market transaction on June 9, 2026, while keeping significant direct and indirect holdings plus various stock options and restricted stock units.

How many Neogenomics (NEO) shares does Lynn A. Tetrault hold after the reported sale?

After the sale, Lynn A. Tetrault held 91,422 Neogenomics common shares directly and 7,000 shares indirectly through a Lynn Tetrault Rollover IRA, according to the Form 4. These positions are in addition to her reported restricted stock units and stock options.

At what price did Lynn A. Tetrault sell Neogenomics (NEO) shares?

Lynn A. Tetrault sold 5,307 Neogenomics common shares at $11.29 per share. The Form 4 describes this as an open-market or private transaction sale, providing a clear per-share price for the reported disposition on June 9, 2026.

What restricted stock units does Lynn A. Tetrault hold in Neogenomics (NEO)?

The filing shows Lynn A. Tetrault holding 15,970 restricted stock units tied to Neogenomics common stock. Once vested, these units convert into common shares and, as noted, are not subject to expiration, providing additional potential equity exposure beyond her current shareholdings.

What stock options does Lynn A. Tetrault have outstanding in Neogenomics (NEO)?

Lynn A. Tetrault holds several Neogenomics stock option grants, including tranches over 11,069, 16,107, 8,672, 8,353 and other share amounts. Exercise prices range from $8.10 to $41.76, with expiration dates running from 2026 through 2036, all referencing underlying common stock.

Does Lynn A. Tetrault hold Neogenomics (NEO) shares indirectly?

Yes. Beyond her direct holdings, Lynn A. Tetrault indirectly holds 7,000 Neogenomics common shares through a Lynn Tetrault Rollover IRA. This indirect position is disclosed separately from her direct share ownership and equity awards in the Form 4 filing.